Vivalis + Intercell = Valneva
hierbei Daten für ältere Personen ab 56 Jahren ermittelt werden !!
Biologisch: VLA2101
Ganzvirus-inaktivierter SARS-CoV-2-Impfstoff, adjuvantiert mit Cytosin-Phosphor-Guanin (CpG) 1018
in Kombination mit Aluminiumhydroxid (variantenbasiert)
2 Impfungen im Abstand von 28 Tagen
Diese Studie dient zwei Zwecken. Einerseits werden Sicherheits- und Immunogenitätsdaten bei Freiwilligen ab
56 Jahren generiert (Kohorte 1), um die Datenbasis für diese Altersgruppe zu stärken. Andererseits wird ein
Immun-Bridging des VLA2101-Impfstoffs von Valneva zu VLA2001 durchgeführt, ergänzt durch den
entsprechenden Sicherheitsvergleich (Kohorte 2).
https://www.clinicaltrials.gov/ct2/show/NCT04956224
Optionen
| Boardmail an "FashTheRoad" |
Wertpapier: Valneva SE |
Natürlich sind das insgesamt naive Aussagen eines unkundigen Fußball-Stars, da gebe ich Dir recht.
https://youtu.be/rq2VKpEolIE
Short Position wird abgebaut....
http://shorteurope.com/...p?selskapsnavn=Valneva%20Se&land=france
https://www.shortsell.nl/short/VALNEVA
https://www.novavax.com/...ecombinant-nanoparticle-vaccine-technology
Ich vermute, dass im vorletzten und letzten Teil der bildlich gezeigten Herstellungs-Reihenfolge der Stolperstein bezüglich Impfstoff-Reinheit zu finden ist.
Nach Expression der Antigene (Untereinheiten des Spike-Proteins von Covid 19) aus der Insektenzelle, wird daraus das fertige Spike-Protein gebildet, durch Bildung eines sogenannten Multimers (das ist ein Stoff/Molekül, dass aus mehreren verschiedenen, sich wiederholenden Untereinheiten besteht).
Durch Fehler bei der Multimerisierung in das fertige Spike-Protein könnten so einfach Unreinheiten entstehen, wenn sich zum Beispiel die falschen Untereinheiten miteinander verbinden oder die richtigen Untereinheiten sich einfach nicht miteinander verbinden wollen (hier sind Umgebungsbedingungen wie Temperatur,ph-Wert ... entscheidend).
Ich hoffe ich habe euch nicht zu sehr gelangweilt oder verwirrt.....
hat in diesem Video viele Infos zu VALENVA zusammengetragen
https://youtu.be/AaFmSv2eQ8w
Wie wäre es, wenn A.Schwarzer , J.Rechelt nach einem Boxkampf mit C. Stahl über Moral interviewt ?
Der Boxkampf wäre interessant aber das Interview müsste wahrscheinlich eh ausfallen :-)
Der Lügenbaron von Gesundheitsminister müsste eigentlich seinen Posten räumen...
Hab mir das Sky Video über YT (aus rechtlichen Gründen..Blub) angesehen und auch Folgevideos zum Thema. Es geht mMn. nur um Quoten, viele verstehen auch nicht warum das Thema Corona in den Sport getragen wird. Wenn hilft Brücken zu bauen, dann aber gerne mehr davon. Mit Bild wird das aber mMn nichts.
Vielleicht steht bald ein neuer uk-deal vor der Tür!
§
§Valnevas Covid-19 vaccine elicits a stronger immune response with far fewer side effects than the Oxford/AstraZeneca jab, according to trial results published a month after the UK terminated a 1.4bn deal with the French vaccine maker.
The first data from the phase 3 trial showed that participants who were given the Valneva vaccine had more neutralising antibodies than those who received the AstraZeneca shot.
The strong results have renewed concerns about whether the UK government should have abandoned the contract, which was also designed to bolster domestic production capacity for future pandemics.
At the time, people familiar with data from a separate trial to assess booster doses said Valnevas vaccine had performed less well than others. The results of that trial, called Cov-Boost, are yet to be published.
About four-fifths of people aged over 12 in the UK have received a complete course of vaccination. The UK is likely to focus only on shots whose utility in boosting has been demonstrated.
But Clive Dix, former interim head of the UK vaccine task force, said it had been very dangerous to extrapolate from Cov-Boost to assess the vaccines overall performance.
It has come out as superior [to AstraZeneca] on all parameters, which means theres no reason to believe that the vaccine wont get approved, he said.
Shares in Valneva rose 43 per cent on Monday. They fell 42 per cent in one day last month after the UK said it was ending its agreement to purchase at least 100m doses of the vaccine. The government said it had terminated the contract for commercial reasons. Valneva would not comment.
Ministers have been accused of failing to give an adequate explanation for why they suddenly cancelled the contract. Sajid Javid, the health secretary, originally told the House of Commons that the vaccine would not receive regulatory approval.
But Javid was forced to correct the ministerial record, explaining that he had meant to say the vaccine had not yet won approval. That prompted Dix to call for Javids resignation.
Valneva has begun a rolling submission to the UKs Medicines and Healthcare products Regulatory Agency and is preparing to start the application procedure for conditional approval in the EU.
Thomas Lingelbach, Valnevas chief executive, pointed out a flaw in the Cov-Boost trial, saying it boosts very early, after two-and-a-half to three months. Valneva would be running its own trial in real booster settings, when peoples antibody response had significantly waned, he said.
Adam Finn, professor of paediatrics at the University of Bristol and trial chief investigator, said it would be hard to assess the Cov-Boost results when published because we do not know how boosting influences effectiveness.
The trial of more than 4,600 people was smaller than and designed differently to the previous phase 3 studies. The vaccine was compared with the AstraZeneca shot because it is no longer seen as ethical to use a placebo since approved jabs became available. The trial compared antibody levels with those elicited by the AstraZeneca vaccine, rather than producing an overall efficacy rate, based on the numbers who became sick. There were no severe cases of Covid-19 in either group.
Significantly fewer participants receiving the Valneva vaccine suffered from side effects, with no serious adverse events reported. Many countries have restricted the use of the AstraZeneca vaccine to older parts of their population, or dropped it completely, because of a rare blood-clotting side effect.
The UK government had invested in Valnevas Scottish manufacturing plant in Livingston, in part to shore up domestic production of vaccines.
Hannah Bardell, Scottish Nationalist MP for Livingston, said ministers had questions to answer about why they cancelled the Valneva contract. They need to urgently rethink their decision, she said.
The danger, Dix warned, was that the site doesnt get fully developed so the UK would not have the lasting legacy to protect against future pandemics for which it had hoped. Nor did cancelling a contract help the rest of the world, he said.
The government at one fell swoop has basically broken promises and killed off two of the objectives for the vaccines task force, Dix added.
Man darf auch nicht vergessen, dass er während des permanenten Spiel und Trainings Betriebs sich ohnehin nicht impfen lassen kann (empfohlene Sportpause von mind. 3 Tagen, eher ne Woche). Denke er wird es Weihnachten machen lassen.
Optionen
| Boardmail an "iudexnoncalculat" |
Wertpapier: Valneva SE |
Quelle: https://www.tagesschau.de/newsticker/...g-coronavirus-montag-231.html
Neue Impfstoffe müssen beweisen, dass sie zumindest gleich gut oder sein müssen bezüglich Effektivität und Verträglichkeit als bereits zugelassene Impfstoffe, VLA 2001 ist einer davon!!